RESUMO Objetivo Analisar fatores associados à viremia detectável de HIV entre mulheres transexuais/travestis (MTTr), em cinco capitais brasileiras. Métodos Dados referentes à amostra de MTTr com sorologia reagente para HIV e carga viral (CV) detectável, em um estudo transversal entre 2019 e 2021. As variáveis dependentes e independentes foram, respectivamente: dosagem da carga viral, características socioeconômicas/demográficas; uso de álcool/drogas; e autopercepção de saúde mental. Foi utilizada a regressão de Poisson com variância robusta. Resultados Um total de 425 MTTr tiveram resultado reagente para HIV e realizaram dosagem de CV, com 179 (42,0%) detectáveis. Os fatores associados positivamente à detectabilidade foram: serem mais novas (RP=2,26; IC95% 1,13;4,51), piores condições de moradia (RP=2,72; IC95% 1,30;5,68) e saúde mental ruim/muito ruim (RP=1,70; IC95% 1,08;2,66). O uso de antirretroviral foi fator protetor à detectabilidade (RP=0,29; IC95% 0,30;0,61). Conclusão Os fatores associados à não supressão viral apontam vulnerabilidade ligada à identidade de gênero com impacto negativo, mesmo com a maioria em uso da terapia antirretroviral (TARV).

ABSTRACT Objective To analyze factors associated with detectable HIV viremia among transgender women/transvestites (TWT) in five Brazilian capitals. Methods : This was a cross-sectional study using data from a sample of TWT with HIV-positive serology and detectable viral load (VL), between 2019 and 2021. The dependent and independent variables were, respectively: viral load measurement, socioeconomic/demographic characteristics; alcohol/drug use; and self-perceived mental health. Poisson regression with robust variance was used. Results : A total of 425 TWT tested positive for HIV and underwent VL measurement, 179 (42.0%) presented detectable viremia. Factors positively associated with detectability were: younger age (PR=2.26; 95%CI 1.13;4.51), poorer housing conditions (PR=2.72; 95%CI 1.30;5.68) and poor/very poor mental health (PR=1.70; 95%CI 1.08;2.66). The use of antiretroviral drugs was a protective factor against detectability (PR=0.29; 95%CI 0.30;0.61). Conclusion The factors associated with unsuppressed viral load highlight vulnerability related to gender identity that have a negative impact, despite the majority of participants being on antiretroviral therapy (ART).

RESUMEN Objetivo Analizar factores asociados a la viremia detectable del VIH entre mujeres transexuales/travestis (MTTr), en cinco capitales brasileñas. Métodos Datos referentes al muestreo MTTr con serología reactiva para VIH y carga viral detectable (CV), en estudio transversal entre 2019-2021. Las variables dependientes e independientes fueron, respectivamente: medición de carga viral, socioeconómicas/demográficas; consumo de alcohol/drogas; y autopercepción de salud mental. Se utilizó la regresión de Poisson con varianza robusta. Resultados Un total de 425 MTTr dieron positivo para el VIH y se sometieron a pruebas CV, siendo 179 (42,0%) detectables. Los factores asociados positivamente con la detectabilidad fueron: ser más joven (RP=2,26; IC95% 1,13;4,51), peores condiciones de vivienda (RP=2,72; IC95% 1,30;5,68) y salud mental mala/muy mala (RP=1,70; IC95% 1,08;2,66). El uso de medicamentos antirretrovirales fue un factor protector para la detectabilidad (RP=0,29; IC95% 0,30;0,61). Conclusión Los factores asociados a la no supresión viral indican vulnerabilidad ligada a identidad de género con efecto negativo, incluso cuando la mayoría utiliza terapia antirretroviral (TARV).

RESUMO Objetivo Analisar fatores associados à viremia detectável de HIV entre mulheres transexuais/travestis (MTTr), em cinco capitais brasileiras. Métodos Dados referentes à amostra de MTTr com sorologia reagente para HIV e carga viral (CV) detectável, em um estudo transversal entre 2019 e 2021. As variáveis dependentes e independentes foram, respectivamente: dosagem da carga viral, características socioeconômicas/demográficas; uso de álcool/drogas; e autopercepção de saúde mental. Foi utilizada a regressão de Poisson com variância robusta. Resultados Um total de 425 MTTr tiveram resultado reagente para HIV e realizaram dosagem de CV, com 179 (42,0%) detectáveis. Os fatores associados positivamente à detectabilidade foram: serem mais novas (RP=2,26; IC95% 1,13;4,51), piores condições de moradia (RP=2,72; IC95% 1,30;5,68) e saúde mental ruim/muito ruim (RP=1,70; IC95% 1,08;2,66). O uso de antirretroviral foi fator protetor à detectabilidade (RP=0,29; IC95% 0,30;0,61). Conclusão Os fatores associados à não supressão viral apontam vulnerabilidade ligada à identidade de gênero com impacto negativo, mesmo com a maioria em uso da terapia antirretroviral (TARV). transexuaistravestis transexuais travestis MTTr, , (MTTr) brasileiras CV (CV 201 2021 foram respectivamente socioeconômicas/demográficas socioeconômicasdemográficas socioeconômicas demográficas álcool/drogas álcooldrogas álcool drogas robusta 42 17 42,0% 420 0 (42,0% detectáveis RP=2,26 RP226 RP 2 26 (RP=2,26 IC95 IC 1,134,51, 113451 1,13 4,51 1 13 4 51 1,13;4,51) RP=2,72 RP272 72 (RP=2,72 1,305,68 130568 1,30 5,68 30 5 68 1,30;5,68 ruimmuito muito RP=1,70 RP170 70 (RP=1,70 1,082,66. 108266 1,08 2,66 . 08 66 1,08;2,66) RP=0,29 RP029 29 (RP=0,29 0,300,61. 030061 0,30 0,61 61 0,30;0,61) negativo TARV. TARV (TARV) (MTTr 20 202 42,0 (42,0 RP=2,2 RP22 (RP=2,2 IC9 134 1,134,51 11345 113 1,1 451 4,5 1,13;4,51 RP=2,7 RP27 7 (RP=2,7 305 1,305,6 13056 130 1,3 568 5,6 3 6 1,30;5,6 RP=1,7 RP17 (RP=1,7 082 1,082,66 10826 108 1,0 266 2,6 1,08;2,66 RP=0,2 RP02 (RP=0,2 300 0,300,61 03006 030 0,3 061 0,6 0,30;0,61 (TARV 42, (42, RP=2, RP2 (RP=2, 1,134,5 1134 11 1, 45 4, 1,13;4,5 1,305, 1305 56 5, 1,30;5, RP=1, RP1 (RP=1, 1,082,6 1082 10 2, 1,08;2,6 RP=0, RP0 (RP=0, 0,300,6 0300 03 0, 06 0,30;0,6 (42 RP=2 (RP=2 1,134, 1,13;4, 1,305 1,30;5 RP=1 (RP=1 1,082, 1,08;2, RP=0 (RP=0 0,300, 0,30;0, (4 RP= (RP= 1,134 1,13;4 1,30; 1,082 1,08;2 0,300 0,30;0 ( (RP 1,13; 1,08; 0,30;

ABSTRACT Objective To analyze factors associated with detectable HIV viremia among transgender women/transvestites (TWT) in five Brazilian capitals. Methods : This was a cross-sectional study using data from a sample of TWT with HIV-positive serology and detectable viral load (VL), between 2019 and 2021. The dependent and independent variables were, respectively: viral load measurement, socioeconomic/demographic characteristics; alcohol/drug use; and self-perceived mental health. Poisson regression with robust variance was used. Results : A total of 425 TWT tested positive for HIV and underwent VL measurement, 179 (42.0%) presented detectable viremia. Factors positively associated with detectability were: younger age (PR=2.26; 95%CI 1.13;4.51), poorer housing conditions (PR=2.72; 95%CI 1.30;5.68) and poor/very poor mental health (PR=1.70; 95%CI 1.08;2.66). The use of antiretroviral drugs was a protective factor against detectability (PR=0.29; 95%CI 0.30;0.61). Conclusion The factors associated with unsuppressed viral load highlight vulnerability related to gender identity that have a negative impact, despite the majority of participants being on antiretroviral therapy (ART). womentransvestites women transvestites (TWT capitals crosssectional cross sectional HIVpositive VL, , (VL) 201 2021 were respectively measurement socioeconomicdemographic socioeconomic demographic characteristics alcoholdrug alcohol drug selfperceived self perceived used 42 17 42.0% 420 0 (42.0% PR=2.26 PR226 PR 2 26 (PR=2.26 95CI CI 95 1.134.51, 113451 1.13 4.51 1 13 4 51 1.13;4.51) PR=2.72 PR272 72 (PR=2.72 1.305.68 130568 1.30 5.68 30 5 68 1.30;5.68 poorvery very PR=1.70 PR170 70 (PR=1.70 1.082.66. 108266 1.08 2.66 . 08 66 1.08;2.66) PR=0.29 PR029 29 (PR=0.29 0.300.61. 030061 0.30 0.61 61 0.30;0.61) impact ART. ART (ART) (VL 20 202 42.0 (42.0 PR=2.2 PR22 (PR=2.2 9 134 1.134.51 11345 113 1.1 451 4.5 1.13;4.51 PR=2.7 PR27 7 (PR=2.7 305 1.305.6 13056 130 1.3 568 5.6 3 6 1.30;5.6 PR=1.7 PR17 (PR=1.7 082 1.082.66 10826 108 1.0 266 2.6 1.08;2.66 PR=0.2 PR02 (PR=0.2 300 0.300.61 03006 030 0.3 061 0.6 0.30;0.61 (ART 42. (42. PR=2. PR2 (PR=2. 1.134.5 1134 11 1. 45 4. 1.13;4.5 1.305. 1305 56 5. 1.30;5. PR=1. PR1 (PR=1. 1.082.6 1082 10 2. 1.08;2.6 PR=0. PR0 (PR=0. 0.300.6 0300 03 0. 06 0.30;0.6 (42 PR=2 (PR=2 1.134. 1.13;4. 1.305 1.30;5 PR=1 (PR=1 1.082. 1.08;2. PR=0 (PR=0 0.300. 0.30;0. (4 PR= (PR= 1.134 1.13;4 1.30; 1.082 1.08;2 0.300 0.30;0 ( (PR 1.13; 1.08; 0.30;

RESUMEN Objetivo Analizar factores asociados a la viremia detectable del VIH entre mujeres transexuales/travestis (MTTr), en cinco capitales brasileñas. Métodos Datos referentes al muestreo MTTr con serología reactiva para VIH y carga viral detectable (CV), en estudio transversal entre 2019-2021. Las variables dependientes e independientes fueron, respectivamente: medición de carga viral, socioeconómicas/demográficas; consumo de alcohol/drogas; y autopercepción de salud mental. Se utilizó la regresión de Poisson con varianza robusta. Resultados Un total de 425 MTTr dieron positivo para el VIH y se sometieron a pruebas CV, siendo 179 (42,0%) detectables. Los factores asociados positivamente con la detectabilidad fueron: ser más joven (RP=2,26; IC95% 1,13;4,51), peores condiciones de vivienda (RP=2,72; IC95% 1,30;5,68) y salud mental mala/muy mala (RP=1,70; IC95% 1,08;2,66). El uso de medicamentos antirretrovirales fue un factor protector para la detectabilidad (RP=0,29; IC95% 0,30;0,61). Conclusión Los factores asociados a la no supresión viral indican vulnerabilidad ligada a identidad de género con efecto negativo, incluso cuando la mayoría utiliza terapia antirretroviral (TARV). transexualestravestis transexuales travestis MTTr, , (MTTr) brasileñas CV (CV) 20192021. 20192021 2019 2021. 2021 2019-2021 fueron respectivamente socioeconómicas/demográficas socioeconómicasdemográficas socioeconómicas demográficas alcohol/drogas alcoholdrogas alcohol drogas robusta 42 17 42,0% 420 0 (42,0% detectables RP=2,26 RP226 RP 2 26 (RP=2,26 IC95 IC 1,134,51, 113451 1,13 4,51 1 13 4 51 1,13;4,51) RP=2,72 RP272 72 (RP=2,72 1,305,68 130568 1,30 5,68 30 5 68 1,30;5,68 malamuy muy RP=1,70 RP170 70 (RP=1,70 1,082,66. 108266 1,08 2,66 . 08 66 1,08;2,66) RP=0,29 RP029 29 (RP=0,29 0,300,61. 030061 0,30 0,61 61 0,30;0,61) negativo TARV. TARV (TARV) (MTTr (CV 2019202 201 202 2019-202 42,0 (42,0 RP=2,2 RP22 (RP=2,2 IC9 134 1,134,51 11345 113 1,1 451 4,5 1,13;4,51 RP=2,7 RP27 7 (RP=2,7 305 1,305,6 13056 130 1,3 568 5,6 3 6 1,30;5,6 RP=1,7 RP17 (RP=1,7 082 1,082,66 10826 108 1,0 266 2,6 1,08;2,66 RP=0,2 RP02 (RP=0,2 300 0,300,61 03006 030 0,3 061 0,6 0,30;0,61 (TARV 201920 20 2019-20 42, (42, RP=2, RP2 (RP=2, 1,134,5 1134 11 1, 45 4, 1,13;4,5 1,305, 1305 56 5, 1,30;5, RP=1, RP1 (RP=1, 1,082,6 1082 10 2, 1,08;2,6 RP=0, RP0 (RP=0, 0,300,6 0300 03 0, 06 0,30;0,6 20192 2019-2 (42 RP=2 (RP=2 1,134, 1,13;4, 1,305 1,30;5 RP=1 (RP=1 1,082, 1,08;2, RP=0 (RP=0 0,300, 0,30;0, 2019- (4 RP= (RP= 1,134 1,13;4 1,30; 1,082 1,08;2 0,300 0,30;0 ( (RP 1,13; 1,08; 0,30;

Abstract Background Two-Drug Regimens (2DR) have proven effective in clinical trials but real-world data, especially in resource-limited settings, is limited. Objectives To evaluate viral suppression of lamivudine-based 2DR, with dolutegravir or ritonavir-boosted protease inhibitor (lopinavir/r, atazanavir/r or darunavir/r), among all cases regardless of selection criteria. Patients and methods A retrospective study, conducted in an HIV clinic in the metropolitan area of São Paulo, Brazil. Per-protocol failure was defined as viremia above 200 copies/mL at outcome. Intention-To-Treat-Exposed (ITT-E) failure was considered for those who initiated 2DR but subsequently had either (i) Delay over 30 days in Antiretroviral Treatment (ART) dispensation, (ii) ART changed or (iii) Viremia > 200 copies/mL in the last observation using 2DR. Results Out of 278 patients initiating 2DR, 99.6% had viremia below 200 copies/mL at last observation, 97.8% below 50 copies/mL. Lamivudine resistance, either documented (M184V) or presumed (viremia > 200 copies/mL over a month using 3TC) was present in 11% of cases that showed lower suppression rates (97%), but with no significant hazard ratio to fail per ITT-E (1.24, p= 0.78). Decreased kidney function, present in 18 cases, showed of 4.69 hazard ratio (p= 0.02) per ITT-E for failure (3/18). As per protocol analysis, three failures occurred, none with renal dysfunction. Conclusions The 2DR is feasible, with robust suppression rates, even when 3TC resistance or renal dysfunction is present, and close monitoring of these cases may guarantee long-term suppression. TwoDrug Two Drug DR (2DR realworld real world data resourcelimited resource limited settings lamivudinebased lamivudine based ritonavirboosted ritonavir boosted lopinavir/r, lopinavirr lopinavir r (lopinavir/r atazanavirr atazanavir darunavir/r, darunavirr darunavir/r , darunavir darunavir/r) criteria study Paulo Brazil Perprotocol Per 20 copiesmL copies mL outcome IntentionToTreatExposed Intention Treat Exposed ITTE ITT E (ITT-E i (i 3 (ART dispensation ii (ii iii (iii 27 996 99 6 99.6 978 97 8 97.8 5 M184V MV M V (M184V TC 11 97%, 97% (97%) 1.24, 124 1 24 (1.24 p 0.78. 078 0.78 . 0 78 0.78) function 469 4 69 4.6 (p 0.02 002 02 3/18. 318 3/18 (3/18) analysis occurred feasible longterm long term lopinavir/r 2 9 99. 97. (97% 1.24 12 (1.2 07 0.7 7 46 4. 0.0 00 31 3/1 (3/18 (97 1.2 (1. 0. 3/ (3/1 (9 1. (1 (3/ ( (3

ABSTRACT The COVID-19 pandemic in Brazil has been marked by high infection and death rates. The immune response generated by current vaccination might be influenced by previous natural infection, and baseline estimates may help in the evaluation of vaccine-induced serological response. We evaluated previous SARS-CoV-2 testing (RT-PCR), and performed rapid diagnostic tests (RDT) and high throughput electrochemiluminescence immunoassay (ECLIA) before vaccination among people living with HIV (PLWH), users of antiretroviral prophylaxis (PrEP/PEP), and healthcare professionals in an HIV outpatient clinic (HCP-HC). RDT was positive in 25.7% (95% CI: 19-33%) overall, 31.3% (95% CI : 18-45%) among PLWH, 23.7% (95% CI : 14-34%) in PrEP/PEP users and 21.4% (95% CI : 05-28%) in HCP-HC (p=0.548). Diagnostic RT-PCR testing was very limited, even for symptomatic individuals, and whereas all HCP-HC had one test perfomed, only 35% of the patients (PREP/PEP/PLWH) were tested (p<0.0001). Adequate monitoring of post-vaccination humoral response and breakthrough infections including those in asymptomatic cases are warranted, especially in immunologically compromised individuals.

ABSTRACT OBJECTIVE Recognize incident infection to better characterize the groups that fuel HIV epidemic. We propose a simple score to identify recent infections among newly diagnosed patients as a HIV surveillance tool. METHODS Newly diagnosed patients were defined as recent infections when a negative serological test in the previous year was available. Laboratory tests, such as the avidity index (Bio-Rad, according to the CEPHIA protocol), chemiluminescent intensity (CMIA, architect, Abbott), and the nucleotide ambiguity index of partial pol sequences were used as proxies of recency. A simple score based on clinical symptoms of acute retroviral syndrome during the previous year, CD4+ T cell count, and viral load at admission was tested to assess the predictive power, using receiver operating characteristic (ROC) curves, to identify recent cases of infection. RESULTS We evaluated 204 recently diagnosed patients who were admitted to the Ambulatório de Referência em Moléstias Infecciosas de Santo André (Santo André Reference Infectious Diseases Outpatient Clinic), in the metropolitan region of São Paulo, Brazil, recruited between 2011 and 2018. An HIV-negative test in the year prior to enrollment was documented in 37% of participants. The proportion of cases classified as recent infections (less than one year), according to the laboratory proxies were: 37% (67/181) for an avidity index < 40%, 22% (30/137) for a CMIA < 200, and 68% (124/181) for an ambiguity index < 0.5%. Using different combinations of recency definitions, our score showed an area under the ROC curve from 0.66 to 0.87 to predict recency. CONCLUSIONS Using data from patients’ interviews and routine laboratory tests at admission, a simple score may provide information on HIV recency and thus, a proxy for HIV incidence to guide public policies. This simple for the Brazilian public health system and other low- and middle-income countries.

ABSTRACT OBJECTIVE Recognize incident infection to better characterize the groups that fuel HIV epidemic. We propose a simple score to identify recent infections among newly diagnosed patients as a HIV surveillance tool. METHODS Newly diagnosed patients were defined as recent infections when a negative serological test in the previous year was available. Laboratory tests, such as the avidity index (Bio-Rad, according to the CEPHIA protocol), chemiluminescent intensity (CMIA, architect, Abbott), and the nucleotide ambiguity index of partial pol sequences were used as proxies of recency. A simple score based on clinical symptoms of acute retroviral syndrome during the previous year, CD4+ T cell count, and viral load at admission was tested to assess the predictive power, using receiver operating characteristic (ROC) curves, to identify recent cases of infection. RESULTS We evaluated 204 recently diagnosed patients who were admitted to the Ambulatório de Referência em Moléstias Infecciosas de Santo André (Santo André Reference Infectious Diseases Outpatient Clinic), in the metropolitan region of São Paulo, Brazil, recruited between 2011 and 2018. An HIV-negative test in the year prior to enrollment was documented in 37% of participants. The proportion of cases classified as recent infections (less than one year), according to the laboratory proxies were: 37% (67/181) for an avidity index < 40%, 22% (30/137) for a CMIA < 200, and 68% (124/181) for an ambiguity index < 0.5%. Using different combinations of recency definitions, our score showed an area under the ROC curve from 0.66 to 0.87 to predict recency. CONCLUSIONS Using data from patients’ interviews and routine laboratory tests at admission, a simple score may provide information on HIV recency and thus, a proxy for HIV incidence to guide public policies. This simple for the Brazilian public health system and other low- and middle-income countries.

ABSTRACT The world has been dealing with Aids for forty years, covid-19 accentuated societal inequalities and promoted a rupture in care and prevention, including for people living with HIV. We compiled official HIV indicators, analyzed the impact of covid-19 in Brazil, at São Paulo State (SP), and compared it to the municipality of Santo André (in the state of São Paulo), which adopted linkage/retention strategies to mitigate the impact of covid-19. From 2019 to 2020, suppression/adhesion rates remained stable. The number of new treatments decreased both in Brazil (-19.75%) and São Paulo (-16.44%), but not in Santo André, where 80% of new patients started treatment within 30 days from their first TCD4 test (70% in São Paulo and 64% in Brazil). However, PrEP dispensing increased during this period. The distribution of 2,820 HIV self-tests in Santo André lead to only one documented new HIV diagnosis linked to care. Synergistic strategies to swiftly diagnose and connect new cases, ensuring retention as well as rescuing missing patients deserve priority in the fight against HIV, especially in times of covid-19.

ABSTRACT The world has been dealing with Aids for forty years, covid-19 accentuated societal inequalities and promoted a rupture in care and prevention, including for people living with HIV. We compiled official HIV indicators, analyzed the impact of covid-19 in Brazil, at São Paulo State (SP), and compared it to the municipality of Santo André (in the state of São Paulo), which adopted linkage/retention strategies to mitigate the impact of covid-19. From 2019 to 2020, suppression/adhesion rates remained stable. The number of new treatments decreased both in Brazil (-19.75%) and São Paulo (-16.44%), but not in Santo André, where 80% of new patients started treatment within 30 days from their first TCD4 test (70% in São Paulo and 64% in Brazil). However, PrEP dispensing increased during this period. The distribution of 2,820 HIV self-tests in Santo André lead to only one documented new HIV diagnosis linked to care. Synergistic strategies to swiftly diagnose and connect new cases, ensuring retention as well as rescuing missing patients deserve priority in the fight against HIV, especially in times of covid-19.

BACKGROUND A number of Zika virus (ZIKV) sequences were obtained using Next-generation sequencing (NGS), a methodology widely applied in genetic diversity studies and virome discovery. However Sanger method is still a robust, affordable, rapid and specific tool to obtain valuable sequences. OBJECTIVE The aim of this study was to develop a simple and robust Sanger sequencing protocol targeting ZIKV relevant genetic regions, as envelope protein and nonstructural protein 5 (NS5). In addition, phylogenetic analysis of the ZIKV strains obtained using the present protocol and their comparison with previously published NGS sequences were also carried out. METHODS Six Vero cells isolates from serum and one urine sample were available to develop the procedure. Primer sets were designed in order to conduct a nested RT-PCR and a Sanger sequencing protocols. Bayesian analysis was used to infer phylogenetic relationships. FINDINGS Seven complete ZIKV envelope protein (1,571 kb) and six partial NS5 (0,798 Kb) were obtained using the protocol, with no amplification of NS5 gene from urine sample. Two NS5 sequences presented ambiguities at positions 495 and 196. Nucleotide analysis of a Sanger sequence and consensus sequence of previously NGS study revealed 100% identity. ZIKV strains described here clustered within the Asian lineage. MAIN CONCLUSIONS The present study provided a simple and low-cost Sanger protocol to sequence relevant genes of the ZIKV genome. The identity of Sanger generated sequences with published consensus NGS support the use of Sanger method for ZIKV population studies. The regions evaluated were able to provide robust phylogenetic signals and may be used to conduct molecular epidemiological studies and monitor viral evolution.

Abstract INTRODUCTION: Improving HIV diagnostics and treatment is necessary to end the AIDS epidemic. Pooled plasma can be used to identify patients with acute HIV disease, even before serological tests. During dengue outbreaks, patients having symptoms common to other acute viral diseases might seek medical care. METHODS: We evaluated HIV RNA in pooled seronegative dengue samples. RESULTS: After excluding individuals with a known HIV diagnosis, an HIV-1 prevalence of 0.73% [95% confidence interval (CI) 0.23-1.76; 4/546 samples] was found. CONCLUSIONS: Promoting strategies to diagnose these individuals and provide them with medical treatment might be instrumental for controlling the HIV epidemic.

Use of CCR5 antagonists requires previous viral tropism determination. The available methods have high cost, are time-consuming, or require highly trained personnel, and sophisticated equipment. We compared a flow cytometry-based tropism assay with geno2pheno method to determine HIV-1 tropism in AIDS patients, in Bahia, Brazil. We tested peripheral blood mononuclear cells of 102 AIDS patients under antiretroviral therapy by using a cytometry-based tropism assay and geno2pheno assay. Cellular membrane receptors were identified by using CXCR4, CCR5 and CD4 monoclonal antibodies, while detection of cytoplasmic mRNAs for gag and pol HIV regions was achieved by using a labeled probe. Genotypic identification of X4 and R5 tropic viruses was attempted by geno2pheno algorithm. There was a high degree of concordance between cytometry-based tropism assay and geno2pheno algorithm in determination of HIV-1 tropism. Cytometry-based tropism assay demonstrated higher sensitivity and specificity in comparison to geno2pheno, which was used as a gold-standard. One sample could not be amplified by geno2pheno method, but was classified as duotropic by cytometry-based tropism assay. We did not find any association between CD4+ count or plasma HIV-1 RNA viral load and tropism results. The overall performances of cytometry-based tropism assay and geno2pheno assay were almost identical in determination of HIV-1 tropism.

Introdução: Embora a maioria das infecções de HIV-1 no Brasil seja devido ao subtipo B, o Sul do Brasil apresenta uma alta prevalência do subtipo C e formas recombinantes, como CRF31_BC. Este estudo avaliou o impacto da diversidade viral na evolução clínica em uma coorte de pacientes HIV-positivos recém diagnosticados. Métodos: De julho/2004 a dezembro/2005, 135 pacientes anti-HIV reagentes foram recrutados. A região pol parcial foi subtipada por filogenia. Um modelo de equação de estimativa generalizada (GEE) foi utilizado para examinar a relação entre subtipo viral, contagem de células CD4 e níveis de carga viral pré-terapia antirretroviral. Hazard ratio (regressão de Cox) foi utilizada para avaliar os fatores associados à supressão viral (carga viral < 50 cópias/mL em seis meses). Resultados: Os principais subtipos de HIV-1 incluíram B (29,4%), C (28,2%) e CRF31_BC (23,5%). Os subtipos B e C apresentaram uma tendência semelhante no declínio de células CD4. Quando comparados os subtipos não B (C e CRF31_BC) e B, não houve diferença significativa na proporção de pacientes com supressão viral aos seis meses (24 semanas). CD4 mais alto e carga viral mais baixa demonstraram associação independente com supressão viral. Conclusão: Não houve diferença significativa entre os subtipos; entretanto, viremia mais baixa e CD4 mais alto pré-terapia mostraram associação com melhor resposta.

Background: Although most HIV-1 infections in Brazil are due to subtype B, Southern Brazil has a high prevalence of subtype C and recombinant forms, such as CRF31_BC. This study assessed the impact of viral diversity on clinical progression in a cohort of newly diagnosed HIV-positive patients. Methods: From July/2004 to December/2005, 135 HIV-infected patients were recruited. The partial pol region was subtyped by phylogeny. A generalized estimating equation (GEE) model was used to examine the relationship between viral subtype, CD4+ T cell count and viral load levels before antiretroviral therapy. Hazard ratio (Cox regression) was used to evaluate factors associated with viral suppression (viral load < 50 copies/mL at six months). Results: Main HIV-1 subtypes included B (29.4%), C (28.2%), and CRF31_BC (23.5%). Subtypes B and C showed a similar trend in CD4+ T cell decline. Comparison of non-B (C and CRF31_BC) and B subtypes revealed no significant difference in the proportion of patients with viral suppression at six months (week 24). Higher CD4+ T cell count and lower viral load were independently associated with viral suppression. Conclusion: No significant differences were found between subtypes; however, lower viral load and higher CD4+ T cell count before therapy were associated with better response.

Management of children with HIV/AIDS is specially challenging. Age-related issues do not allow for direct transposition of adult observations to this population. CXCR4 tropism has been associated with disease progression in adults. The geno2pheno web-base is a friendly tool to predict viral tropism on envelope V3 sequences, generating a false positive rate for a CXCR4 prediction. We evaluated the association of HIV-1 tropism prediction with clinical and laboratory outcome of 73 children with HIV/AIDS in São Paulo, Brazil. The CXCR4 tropism was strongly associated with a lower (nadir) CD4 documented during follow-up (p < 0.0001) and with disease severity (clinical event and/or CD4 below 200 cells/mm3) at the last observation, using commonly applied clinical cutoffs, such as10%FPRclonal (p = 0.001). When variables obtained during follow-up are included, both treatment adherence and viral tropism show a significant association with disease severity. As for viremia suppression, 30% (22/73) were undetectable at the last observation, with only adherence strongly associated with suppression after adjustment. The study brings further support to the notion that antiretroviral treatment adherence is pivotal to management of HIV disease, but suggests that tropism prediction may provide an additional prognostic marker to monitor HIV disease in children.